Yesterday we spent time with the #Incyte team as part of our ongoing collaboration.

It’s always valuable to hear the science directly from the people behind it and think together about how visual strategy can support their goals.

Conversations like these are where strong scientific visuals begin!

Joy as NICE changes tack on first NHS vitiligo treatment NHS patients in England with vitiligo will soon be able to access Incyte's Opzelura, the first drug shown to reverse the skin-lightening disorder.

#NICE #NHS #vitiligo #vitiligotreatment #NICEnews #skinlighteningdisorder #NICEapprovedtreatment #Reimbursement #Incyte #JAKinhibitorcream #Opzelura #ruxolitinib #facialvitiligo #JAKsignallingpathway #TheVitiligoSociety #oralJAKinhibitors #skindisorder #dermatology
zurl.co/dZyqZ

Dr. @ertrunnell.bsky.social thanks for posting. While there is much yet to do, think in not too distant future #GigaTIME will have a major impact in tailoring therapies to patients with #cancer #GSK #Astrazeneca #Regeneron #Abbvie #incyte #FDA #NCI #FinishCancer

Empowering Through Visibility: Winnie Harlow Partners With Incyte To Support People With Vitiligo Winnie Harlow has always been more than a supermodel, she’s a symbol of redefined beauty, resilience, and representation. Now, she’s channeling her… The post Empowering Through Visibility: Winnie Harlow Partners With Incyte To Support People With Vitiligo appeared first on Shine My Crown.

Empowering Through Visibility: Winnie Harlow Partners With Incyte To Support People With Vitiligo: Winnie Harlow has always been more than a supermodel, she’s a symbol of redefined beauty, resilience, and representation.… #WinnieHarlow #VitiligoAwareness #Incyte #BeautyInDiversity #RedefiningBeauty

Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

Up and Down the Ladder: Job Changes... the latest comings & goings.. recognize anyone? statnews.com/pharmalot/20... #pharma #biotech #jobs #Gilead #Incyte

How Is Incyte’s Stock Performance Compared to Other Biotech Stocks? - Yahoo Finance How Is Incyte’s Stock Performance Compared to Other Biotech Stocks?  Yahoo Finance

Click Subscribe #Investing #BiotechStocks #StockMarket #FinanceNews #Incyte

Incyte stock falls after FDA extends review of pediatric eczema cream Investing.com -- Incyte Corporation (NASDAQ:INCY) stock fell 2.2% Monday after reporting Friday that the U.S. Food and Drug Administration extended its review period for the company’s topical treatment for children with atopic dermatitis. The FDA pushed back the Prescription Drug User Fee Act action date for ruxolitinib cream (Opzelura) by three months to September 19, 2025. The extension will allow regulators time to review additional chemistry, manufacturing and controls data for the 0.75% strength formulation that Incyte submitted in response to a recent information request. The supplemental New Drug Application seeks approval for Opzelura to treat mild to moderate atopic dermatitis in children aged 2-11 years. The submission was based on data from the Phase 3 TRuE-AD3 study, which met its primary endpoint with significantly more patients achieving Investigator’s Global Assessment-treatment success compared to those receiving the vehicle control. "Atopic dermatitis is a chronic immune-mediated skin condition that can be difficult to manage, particularly for the millions of children in the U.S. affected by AD," said Steven Stein, Chief Medical Officer at Incyte. "We are confident in the potential of ruxolitinib cream to become an important non-steroidal, topical treatment option for pediatric patients." The company reported that the treatment demonstrated a safety profile consistent with previous data, with no serious infections, major adverse cardiovascular events, malignancies or thromboses reported during the 8-week vehicle-controlled period. The most common treatment-related adverse event was application site pain, occurring in 2.7% of patients treated with Opzelura versus 0% in the vehicle arm. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #Incyte #StockMarket #FDAApproval #EczemaTreatment #PediatricHealth

IncyteのMonjuvi®（タファシタマブ-cxix）がFDAに承認！再発・難治性の濾胞性リンパ腫に対し、リツキシマブ、レナリドミドとの併用療法として新たな選択肢。患者さんのQOL向上に期待！ 濾胞性リンパ腫 #Monjuvi #タファシタマブ #FDA承認 #Incyte #血液がん #新薬 Link

Specialised Therapeutics and Incyte Announce Expanded Partnership for New Therapies Specialised Therapeutics and Incyte expand their partnership to include two additional therapies aimed at addressing hard-to-treat conditions in the Asia-Pacific region.

Specialised Therapeutics and Incyte Announce Expanded Partnership for New Therapies #Singapore #Incyte #Specialised_Therapeutics #Oncology_Therapies

FDA Approves Niktimvo: A Game-Changer for Chronic GVHD Patients Niktimvo's FDA approval marks a major advance in chronic GVHD treatment, targeting inflammation and fibrosis with proven efficacy across various patient groups.

FDA Approves Niktimvo: A Game-Changer for Chronic GVHD Patients #United_States #Wilmington #Niktimvo #Syndax #Incyte

The Top Sponsors in Rare Diseases Clinical Trials Initiations ✔ Brazil SFE® - André Luiz Bernardes ♕Data Science ✰BI, Big Data & Analytics, ✰Market Intelligence, ♕Sales Force Effectiveness...

brazilsfe.blogspot.com/2024/11/blog...
The Top Sponsors in Rare Diseases Clinical Trials Initiations
✔ Brazil SFE®

#Roche #AstraZeneca #Merck #BristolMyersSquibb #Pfizer #HengruiPharma #SinoBiopharmaceutical #Novartis #AbbVie #Incyte #JohnsonandJohnson #Sanofi #EnsaiosClínicos

Syndax Pharmaceuticals and Royalty Pharma Announce $350 Million Royalty Funding Agreement for Niktimvo™ Syndax Pharmaceuticals has entered into a substantial $350 million royalty funding agreement with Royalty Pharma, focused on the U.S.

www.linkedin.com/pulse/syndax...

Syndax Pharmaceuticals and Royalty Pharma Announce $350 Million Royalty Funding Agreement for Niktimvo™

#SyndaxPharma #RoyaltyPharma #Niktimvo #GVHD #BiotechFunding #Incyte #Biotechnology #Humanteconomy #Humantech